Pioglitazone

CHEMBL595 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

356.4 g/mol

LogP

3.8

Phase

4

Used to improve blood sugar control in adults with type 2 diabetes by making the body's cells more sensitive to insulin, and also has beneficial effects on cardiovascular risk factors. It is often used in combination with other diabetes medications when blood sugar is not adequately controlled.

Masse moléculaire

356,4000 g/mol

LogP

3,80

TPSA

93,60 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Melanoma Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1

InChI

InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)

Molecular Formula

C19H20N2O3S

HBD / HBA

1 / 5

Liaisons Rotatives

7

Atomes Lourds

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Used to improve blood sugar control in adults with type 2 diabetes by making the body's cells more sensitive to insulin, and also has beneficial effects on cardiovascular risk factors. It is often used in combination with other diabetes medications when blood sugar is not adequately controlled.

Yes, Pioglitazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL595. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4829. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Pioglitazone sur PillFYI

Structure

Données Clés

Formule: C19H20N2O3S
Synonymes: 5

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.